Management of cardiometabolic risk factors in cardiovascular high-risk populations with varying cognitive levels Authors: Ting Shen, Meiqi Zhao, Siyuan Qiao, Zejun Yang, Mingxiao Li, Manlin Zhao, Jiaxin Liu, Meilin Xu, Yu Kong, Xin Li, Liu He, Changsheng Ma Published: 2025 ABSTRACT AbstractBackgroundCognitive impairment may hinder effective self-management of cardiovascular disease and lead to worsening cardiovascular risk.AimsThis study aimed to describe the rate of uncontrolled blood pressure, blood lipids, and blood glucose across different cognitive levels to identify priority groups for managing risk factors in patients with cardiovascular disease.MethodsA total of 10,707 patients with cardiovascular disease or individuals at high cardiovascular risk were enrolled from Beijing Anzhen Hospital. Cognitive function, assessed using the Montreal Cognitive Assessment (MoCA) scale, was categorized as normal (MoCA ≥ 26) or impaired (MoCA < 26). Logistic regression was used to explore the association between cognitive function and the rates of uncontrolled blood pressure, lipids, and glucose.ResultsAmong diabetic patients, the rate of uncontrolled blood glucose in those with cognitive impairment was significantly higher in patients with cognitive impairment than in those with normal cognition [hemoglobin A1c ≥ 7%, 65.7% vs. 56.6%, adjusted odds ratio (aOR) (95% confidence interval, 95% CI):1.40(1.21–1.62), P < 0.001]. The rate of uncontrolled blood pressure and blood lipids were slightly higher in cognitive impairment than normal cognition, however, the differences were not statistically significant [systolic blood pressure(SBP) ≥ 130mmHg and/or diastolic blood pressure(DBP) ≥ 80mmHg, 74.6% vs. 70.5%, aOR(95% CI):1.07 (0.96–1.20), P = 0.206; SBP ≥ 140mmHg and/or DBP ≥ 90mmHg, 45.4% vs. 40.0%, aOR(95% CI):1.08(0.98–1.91), P = 0.125; poor blood lipids management, 72.2% vs. 70.5%, aOR (95% CI):1.00(0.89–1.13), P = 0.994].ConclusionsIn this cross-sectional study, a significant association was observed between cognitive impairment and an unfavorable cardiovascular risk profile. This may reflect challenges in self-management and underscores the need for proactive care.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40520-025-03241-y.Keywords: Cognitive impairment, Cardiovascular disease, Cardiovascular risk factors, Hypertension, Hyperlipidemia, Diabetes Introduction Cognitive impairment and cardiovascular disease (CVD) are increasingly prevalent and often coexist in the aging population, resulting in a substantial economic and social burden [1–5]. Dementia is a devastating neurodegenerative disease affecting more than 50 million individuals worldwide [6]. Notably, cognitive impairment is a continuous spectrum, with cognitive function declining gradually across stages. Clinically, it typically starts with mild cognitive impairment (MCI), characterized by subtle deficits that are noticeable but do not significantly interfere with daily life. It then progresses to moderate impairment (affecting instrumental activities of daily living) and may advance to severe impairment or dementia if unaddressed [7, 8]. The management of patients with comorbid chronic diseases requires a combination of pharmacological treatment and lifestyle modifications for effective control. However, these strategies depend on adequate cognitive function to ensure proper implementation [9–13]. Patients with normal cognition can be managed through health education, medication adherence, and lifestyle modifications. In contrast, patients with cognitive impairment may experience deficits in memory, language, problem-solving, and executive function [14], affecting instrumental activities of daily living [15, 16] and leading to suboptimal adherence to medical advice [9, 12]. These cognitive deficits can significantly hinder self-management and treatment adherence by impairing patients’ capacity to understand complex treatment regimens, recognize early disease symptoms, and effectively communicate with healthcare providers [17]. As a result, managing common cardiovascular risk factors (CVRF)—such as medication adherence, regular monitoring of blood pressure (BP), blood glucose, and lipid levels, adherence to dietary sodium and fluid restrictions, weight management, physical activity, and timely healthcare utilization—becomes particularly challenging in this population [17–19]. Therefore, external interventions are essential to enhance monitoring, optimize adherence, and support proactive management. Currently, there is a lack of data on the prevalence of uncontrolled BP, blood lipids, and blood glucose among patients with both CVD and cognitive impairment. Therefore, this study aims to provide valuable insights into the current status of HTN, hyperlipidemia, and diabetes in patients with cognitive impairment respectively. Additionally, this study was designed to offer updated estimates to inform public health strategies to manage cardiovascular risks in populations with cognitive impairment. Materials and methods Data availability statement This cross-sectional study used data from the hospital’s electronic medical record system. The datasets generated and analyzed during the current study are not publicly available due to patient privacy protection, but are available from the corresponding author on reasonable request. Study population A total of 39,962 patients from the Department of Cardiology at Beijing Anzhen Hospital who underwent cognitive health assessment were enrolled in this study from January 2019 to October 2023. Eligible patients were aged 18 years, had a medical history of either HTN, hyperlipidemia, or diabetes, and had available measurements of BP (BP measured at least twice), blood lipids, and hemoglobin A1c (HbA1c). Patients with systolic blood pressure (SBP) lower than 90 mmHg or higher than 180 mmHg and diastolic blood pressure (DBP) lower than 60 mmHg or higher than 120 mmHg were excluded. Finally, 10,707 eligible patients were recruited in this study. A flow diagram of the study is presented in Fig. 1. Study flow diagram In addition, detailed demographic information and clinical data were collected from electronic medical records. The demographic information included age, sex, and education status. The clinical data encompassed body mass index (BMI), smoking status, alcohol consumption, medical history [including HTN, coronary artery disease (CAD), heart failure (HF), atrial flutter/atrial fibrillation, valvular heart disease, primary cardiomyopathy, stroke, transient ischemic attack, Parkinson’s disease, obstructive sleep apnea, dyslipidemia, diabetes, malignant tumor], cognitive health assessment [including Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE)], other mental health assessment [including Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), Pittsburgh Sleep Quality Index (PSQI)], laboratory test results (including blood lipids, blood glucose, brain natriuretic peptide, estimated glomerular filtration rate, and high-sensitivity C-reactive protein), and imaging examination findings of left ventricular ejection fraction. The Institutional Review Board of Beijing Anzhen Hospital approved this specific study. The study was performed according to the ethical principles in the Declaration of Helsinki. Informed consent was waived because of the retrospective nature of the study, and the analysis used anonymous clinical data. Cognitive assessment The MoCA was used to evaluate the cognitive function, and it is a 10-minute cognitive screening tool to assist first-line physicians in detecting mild cognitive impairment (MCI) with high sensitivity and specificity [20]. The MoCA scale has a maximum score of 30, encompassing eight cognitive domains: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall, and orientation. A final total score of 26 and above indicates normal cognitive function, and a score below 26 indicates potential cognitive impairment. A further distinction was made when the score was below 26. A score between 19 and 25 was defined as MCI, and a score below 19 was defined as dementia [21]. To describe the mental health of the population extensively, the MMSE scale was also used to evaluate cognitive function. The MMSE score ≥ 27 indicates normal cognition, and < 27 indicates a higher risk of cognitive impairment [22]. Mental health assessment The PSQI scale is used to evaluate sleep quality, a score ≤ 5 indicates good sleep quality, and a score >5 indicates poor sleep quality [23]. The SAS scale is used to evaluate anxiety, a score < 50 indicates no anxiety, and a score ≥ 50 indicates anxiety [24]. The SDS scale is used to evaluate the depression status, a score < 53 indicates no depression, a score ≥ 53 indicates depression [25]. Control target of cardiometabolic risk factors The data of blood lipids and blood glucose were obtained by biochemical testing, and the BP values were obtained through physical examination at admission and were measured at least twice, and the average value represented the final BP. All data were collected within three months before or at the time of the current cognitive health assessment. The 2024 ESC Guidelines for the management of elevated BP and HTN recommend that the primary goal of blood pressure treatment should be to achieve SBP < 140 mmHg and DBP < 90 mmHg in all patients. If treatment is well tolerated, the target should be further reduced to SBP < 130 mmHg and DBP < 80 mmHg or lower in most patients [26]. In addition, the control target (SBP < 130 mmHg and DBP < 80 mmHg) of HTN was also estimated according to the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline. Consequently, the study had two goals to compare the rate of uncontrolled blood pressure using two different criteria. The rate of uncontrolled HTN was defined as the proportion of patients with uncontrolled hypertension (HTN, SBP ≥ 140mmHg and/or DBP ≥ 90mmHg, and SBP ≥ 130mmHg and/or DBP ≥ 80mmHg) [27]. The HbA1c is the gold standard for evaluating blood glucose control in diabetic patients, serving as a surrogate biochemical marker for average glycemia over the previous 2–3 months [28]. Therefore, this study used HbA1c to measure glycemic levels. According to the Glycemic Targets: Standards of Care in Diabetes-2023, the target HbA1c level was set as < 7% [29], and HbA1c ≥ 7% was defined as uncontrolled diabetes. In previous ESC/EAS guidelines for the management of dyslipidemia [30, 31] and other major guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk [32, 33], the importance of low-density lipoprotein cholesterol (LDL-C) lowering to prevent CAD is strongly emphasized. Risk stratification for blood lipids is conducted by the Chinese Guidelines for Lipid Management (2023) [34]. According to the laboratory indexes and medical history, patients were classified into four levels: low risk, medium and high risk, very high risk, and ultra-high risk, with treatment goals tailored to the total CV risk level. The recommended LDL-C target values are as follows: below 3.4 mmol/L for low risk, below 2.6 mmol/L for medium and high risk, below 1.8 mmol/L for very high risk, and below 1.4 mmol/L for ultra-high risk. The proportion of patients whose blood lipid control fails to meet the standard is the rate of uncontrolled blood lipids. Statistical analysis Continuous variables following a normal distribution are expressed as mean (standard deviation, SD), and the Student’s T-test is used for comparison between groups. For non-normally distributed data, the results are presented as median (interquartile range, IQR) and compared using the Mann-Whitney U test. Categorical variables are represented as percentages and analyzed for group comparisons using the χ2 test. As a cross-sectional study, the associations between the cognitive function levels and the rates of uncontrolled blood pressure, blood lipids, and blood glucose were evaluated using logistic regression models, adjusting for confounders. Cognitive impairment was further divided into MCI and dementia. Directed acyclic graphs (DAGs) were constructed based on a review of the literature and clinical expertise to identify the confounders in this study. For blood pressure control, the following covariates were adjusted for: sex (female/male), age (continuous), education level (bachelor’s degree or above vs. below bachelor’s degree), anxiety (Yes/No), depression (Yes/No), smoking status (current/former or never), alcohol consumption (current/former or never), CAD (Yes/No), HF (Yes/No), and atrial flutter/fibrillation (Yes/No) (Figure S1). Regarding blood lipid control, the following covariates were adjusted for: sex, age, education level, anxiety, depression, smoking history, alcohol consumption, CAD, HF, atrial flutter/fibrillation, HTN, and diabetes (Figure S2). The blood glucose control was adjusted for sex, age, education status, anxiety, depression, smoking history, and alcohol consumption (Figure S3). The rate of uncontrolled blood pressure was compared among hypertensive patients stratified by different levels of cognitive function; simultaneously, the rate of abnormal blood lipids was compared among hyperlipidemic patients and the rate of abnormal blood glucose among diabetic patients. In addition, restricted cubic splines were plotted to provide a clearer and more intuitive illustration of these associations. Besides, subgroup analysis was performed according to age (< 65, 65–74, and ≥ 75 years), sex, BMI (< 18.5, 18.5–23.9, and ≥ 24 kg/m2), education status (bachelor’s degree and above vs. below bachelor’s degree), medical history of stroke, and medical history of HF in the rate of uncontrolled blood pressure. Regarding blood lipids control, subgroup analyses were performed according to age, sex, BMI, education status, medical history of stroke, and medical history of CAD. As for blood glucose control, subgroup analyses were performed according to age, sex, BMI, education status, and medical history of stroke. To examine potential non-linear relationships, a restricted cubic spline (RCS) model was fitted for the continuous Montreal Cognitive Assessment (MoCA) score in relation to uncontrolled risk factors. This approach allowed for a visual assessment of the dose-response trend between cognitive function and the probability of risk factor control. The statistical significance threshold was set at a two-tailed P-value of 0.05. All statistical analyses were performed using R version 4.4.2. Results Study population and baseline characteristics The characteristics of the study population are presented in Table 1. In this study, a total of 10,707 patients were finally included. Among the patients, 4994 (41.2%) had normal cognitive function, and 5713 (53.4%) had cognitive impairment. Compared with normal cognition patients, patients with cognitive impairment were older (mean age: 64.7 yrs vs. 58.5 yrs), with less proportion of males (64.3% vs. 78.7%), and less proportion of patients who have a bachelor’s degree or higher (7.4% vs. 24.1%). Additionally, HTN (75.2% vs. 68.4%), diabetes (42.5% vs. 38.0%), CAD (91.5% vs. 87.1%), stroke (13.0% vs. 7.0%), and HF (6.7% vs. 5.4%) were more prevalent in patients with cognitive impairment, indicating a higher burden of cardiovascular comorbidities in this population. Table 1Characteristics of the 999 women according to quintiles of serum total osteocalcin at baseline (age 75)CharacteristicsQ1n = 199Q2n = 201Q3n = 199Q4n = 201Q5n = 199s-total osteocalcin (ng/mL)*14.8(4.9)21.9(2.3)26.2(2.4)32.7(3.5)44.2(13.0)Age (years)75.2(0.2)75.2(0.1)75.2(0.1)75.2(0.1)75.2(0.2)Weight (kg)*72.0(18)69.0(13)66.0(14)65.0(15)65.0(15)Height (cm)160.9(5.6)161.1(5.3)160.0(5.8)160.9(5.6)160.0(6.0)Body Mass Index (kg/m2)*27.0(6.5)26.5(5.3)25.6(5.0)25.3(4.5)25.1(5.1)Frailty index*aRange0.210.05–0.67(0.16)0.160.05–0.53(0.13)0.150.02–0.74(0.13)0.130.01–0.45(0.10)0.160.01–0.73(0.13)s-PINP (ng/mL)*28.7(15.7)41.9(13.8)47.1(16.7)55.0(17.5)74.0(27.4)s-CTX (ng/L)*119.9(115.4)225.2(120.7)272.9(145.8)330.0(186.1)510.3(249.3)s-25(OH)D3 (nmol/L)*59(25)62(28)63(23)62(29)57(28)s-PTH (pmol/L)*4.0(2.1)4.1(2.1)3.8(2.2)4.3(2.3)5.4(3.1)p-calcium (mmol/L)*2.4(0.1)2.4(0.1)2.4(0.1)2.4(0.1)2.4(0.1)eGFR cysC (mL/min/1.73m2)65(18)67(17)64(18)64(18)57(18)BMD, femoral neck (g/cm2)*0.797(0.208)0.765(0.189)0.747(0.184)0.740(0.148)0.719(0.177)T-score, fem. neck (SD)*− 1.5(1.7)−1.8(1.6)− 1.9(1.5)− 2.0(1.2)− 2.2(1.5)Lean muscle mass, legs(kg/m2)*4.7(0.7)4.7(0.6)4.6(0.7)4.6(0.6)4.7(0.6)Total body fat mass (kg/m2)*10.6(4.2)10.6(3.9)9.9(4.1)9.7(3.3)9.7(4.2) No. % No. % No. % No. % No. % Recent osteoporotic fracture (age 73–75)14(7)17(9)21(11)17(9)19(10)Fallen within the last year49(27)56(32)52(30)44(24)51(29)Frail individualsb72(36)44(22)43(22)26(13)46(23)Current smoker24(12)30(15)32(16)23(12)29(15)Alcohol abstainer46(23)27(14)36(19)40(20)44(22)Glucocorticoids, current user11(6)7(4)5(3)2(1)3(2)Bisphosphonates, current user22(11)5(3)2(1)0(0)1(1)*Median (IQR); aFrailty index (cut-off range 0.0–1.0 on each variable); bFrail status (frailty index ≥ 0.25)s-PINP = Serum intact N-terminal propeptide of type I collagens-CTX = Serum C-terminal crosslinked telopeptide of type I collagen Characteristics of the 999 women according to quintiles of serum total osteocalcin at baseline (age 75) Frailty index*a Range 0.21 0.05–0.67 0.16 0.05–0.53 0.15 0.02–0.74 0.13 0.01–0.45 0.16 0.01–0.73 Lean muscle mass, legs (kg/m2)* *Median (IQR); aFrailty index (cut-off range 0.0–1.0 on each variable); bFrail status (frailty index ≥ 0.25) s-PINP = Serum intact N-terminal propeptide of type I collagen s-CTX = Serum C-terminal crosslinked telopeptide of type I collagen Association between cognition and the management of BP, blood lipids, and blood glucose The rate of uncontrolled blood glucose in the cognitive impairment patients was higher than patients in the normal cognition group [HbA1c ≥ 7%, 65.7% vs. 56.6%, adjusted odds ratio (aOR) (95% confidence interval [CI]): 1.40 (1.21–1.62), p < 0.001]. Compared with the normal cognition group, the cognitive impairment group showed a non-significant higher rate in BP control [SBP ≥ 130mmHg and/or DBP ≥ 80mmHg, 74.6% vs. 70.5%, aOR (95% CI): 1.07 (0.96–1.20), P = 0.206; SBP ≥ 140mmHg and/or DBP ≥ 90 mmHg, 45.4% vs. 40.0%, aOR (95% CI): 1.08 (0.98–1.91), P = 0.125]. The rate of uncontrolled blood lipids was similarly comparable [72.2% vs. 70.5%, aOR (95%CI): 1.00 (0.89–1.13), P = 0.994] (Table 2). Table 2Normal cognition versus cognitive impairment in the rate of uncontrolled blood pressure, blood glucose, and blood lipidsNormal cognition(MOCA ≥ 26)Cognitive impairment(MOCA<26)*P valueAdjusted OR(95%CI)**P-valuea SBP ≥ 130mmHg and/or DBP ≥ 80 mmHg, (%)2410(70.5)3208(74.6)< 0.0011.07(0.96–1.20) 0.206 a SBP ≥ 140mmHg and/or DBP ≥ 90 mmHg, (%)1368(40.0)1954(45.4)< 0.0011.08(0.98–1.91) 0.125 b Failed to achieve the lipid target, (%)2472(70.5)2562(72.2)0.1161.00(0.89–1.13) 0.994 c HbA1c ≥ 7%, (%)990(56.6)1408(65.7)< 0.0011.40(1.21–1.62) < 0.001 *P-value derived from the chi-square test**P-value derived from logistic regression analysisOR, odds ratio; CI, confidence Interval; SBP, systolic blood pressure; DBP, diastolic blood pressurea Adjusted for sex, age, education level, anxiety, depression, smoking, alcohol consumption, coronary artery disease, heart failure, and atrial flutter/ atrial fibrillationb Adjusted for sex, age, education level, anxiety, depression, smoking, alcohol consumption, coronary artery disease, heart failure, atrial flutter/ atrial fibrillation, HTN, and diabetesc Adjusted for sex, age, education level, anxiety, depression, smoking, and alcohol consumption Normal cognition versus cognitive impairment in the rate of uncontrolled blood pressure, blood glucose, and blood lipids *P-value derived from the chi-square test **P-value derived from logistic regression analysis OR, odds ratio; CI, confidence Interval; SBP, systolic blood pressure; DBP, diastolic blood pressure a Adjusted for sex, age, education level, anxiety, depression, smoking, alcohol consumption, coronary artery disease, heart failure, and atrial flutter/ atrial fibrillation b Adjusted for sex, age, education level, anxiety, depression, smoking, alcohol consumption, coronary artery disease, heart failure, atrial flutter/ atrial fibrillation, HTN, and diabetes c Adjusted for sex, age, education level, anxiety, depression, smoking, and alcohol consumption Additionally, an assessment was conducted on the impact of distinct levels of cognitive impairment on the rate of uncontrolled blood pressure. Compared with the normal cognition group, the MCI group showed a non-significant increase in the rate of uncontrolled blood pressure [SBP ≥ 130mmHg and/or DBP ≥ 80mmHg, 73.6% vs. 70.5%, aOR (95%CI): 1.04 (0.93–1.16), P = 0.462; SBP ≥ 140mmHg and/or DBP ≥ 90mmHg, 44.7% vs. 40.0%, aOR (95%CI): 1.07 (0.97–1.18), P = 0.178]. The dementia group shows a significant increase compared to normal cognition [SBP ≥ 130mmHg and/or DBP ≥ 80mmHg, 81.9% vs. 70.5%, aOR (95%CI):1.49 (1.17–1.92), P = 0.001; SBP ≥ 140mmHg and/or DBP ≥ 90mmHg, 50.4% vs. 40.0%, aOR (95%CI):1.17 (0.96–1.42), P = 0.121]. The results indicated that a higher severity of cognitive impairment was associated with a higher rate of uncontrolled blood pressure (Table 3). Table 3Components of frailty index (continuous or categorical variables as appropriate) in relation to quintiles of osteocalcinOsteocalcinQ1n = 158Q2n = 175Q3n = 173Q4n = 182Q5n = 176s-total osteocalcin (ng/mL)15.2 (4.6)22.0 (2.2)26.2 (2.3)32.6 (3.4)44.5 (13.7) Frailty index component Median (IQR)/SimplePara> Median (IQR) Median (IQR) Median (IQR) Median (IQR) Uncorrected p-value, overall(p-value, Q1vs. Q5) Corrected p-value Muscle strength – knee extension (Nms)263 (124)282 (106)270 (106)274 (83)261 (122)0.296 (0.484)0.025Average time spent outdoor (hours)2.5 (1.8)3.0 (1.9)2.5 (1.9)2.8 (1.9)2.5 (1.9)0.012 (0.158)0.007Gait – walking speed (m/s) for 2 × 15 m1.3 (0.4)1.4 (0.3)1.3 (0.3)1.4 (0.4)1.4 (0.4)< 0.001 (0.001)0.005Gait – no. of steps taken, walking 2 × 15 m49 (9)47 (6)47 (9)47 (8)47 (9)0.004 (0.003)0.006Balance (right leg, eyes open) (s)10 (21)15 (22)15 (21)17 (22)15 (24)0.007 (0.011)0.006p-CRP (mg/L)3.0 (4.3)2.0 (2.6)1.9 (2.6)1.5 (2.3)1.6 (3.0)< 0.001 (< 0.001)0.004p-creatinine (µmol/L)74 (16)73 (16)74 (19)73 (17)77 (20)0.100 (0.093)0.013 N (%) N (%) N (%) N (%) N (%) p for trend Low mobility/activity level22 (14)10 (6)13 (8)11 (6)21 (12)0.0230.008Diabetes27 (18)12 (7)9 (5)4 (2)5 (3) < 0.001 0.004Cancer/severe disease28 (18)27 (16)22 (13)26 (14)27 (16)0.7400.050Disease(s) affecting balance, actual35 (26)28 (19)33 (23)25 (15)37 (25)0.1330.017Polypharmacy (≥ 5 medications)46 (29)28 (16)29 (17)20 (11)29 (17) < 0.001 0.005High self-estimated risk of falling19 (14)16 (11)9 (6)9 (6)13 (8)0.0510.010Bisphosphonate and glucocorticoid users and/or women with recent fracture (fr. 73–75 years of age) excluded (n = 135). P-values corrected for multiple comparison using Holm-Bonferroni methodMuscle strength: maximal knee extension, isometric contraction at 90˚ (Nms). Low mobility/activity level: ranging from walking with aid to bedridden (corresponding to cat. 1–4 on a scale from 1–8, with lower number indicating lower mobility level). Diabetes: diabetes at visit (yes/no). Cancer/severe disease: self-reported. Diseases affecting balance: self-reported. High self-estimated risk of falling: self-reported, those with fall risk cat. 4 and 5 on a scale from 1–5 (with higher number indicating higher risk) [21]. Bold numbers indicate statistically significant p-values (i.e. p < 0.05) after correcting the raw p-values using the Holm-Bonferroni method Components of frailty index (continuous or categorical variables as appropriate) in relation to quintiles of osteocalcin Bisphosphonate and glucocorticoid users and/or women with recent fracture (fr. 73–75 years of age) excluded (n = 135). P-values corrected for multiple comparison using Holm-Bonferroni method Muscle strength: maximal knee extension, isometric contraction at 90˚ (Nms). Low mobility/activity level: ranging from walking with aid to bedridden (corresponding to cat. 1–4 on a scale from 1–8, with lower number indicating lower mobility level). Diabetes: diabetes at visit (yes/no). Cancer/severe disease: self-reported. Diseases affecting balance: self-reported. High self-estimated risk of falling: self-reported, those with fall risk cat. 4 and 5 on a scale from 1–5 (with higher number indicating higher risk) [21]. Bold numbers indicate statistically significant p-values (i.e. p < 0.05) after correcting the raw p-values using the Holm-Bonferroni method Compared to normal cognition, MCI did not show a significant difference in the rate of uncontrolled blood lipids [72.0% vs. 70.5%, aOR (95%CI): 0.99 (0.89–1.12), P = 0.875], dementia showed a non-significant difference [73.9% vs. 70.5%, aOR (95%CI): 1.10(0.85–1.42), P = 0.483] (Table 3; Fig. 2). The association between MoCA scores and the rate of uncontrol blood pressure, blood lipids, and blood glucose. A, Restricted cubic spline curves showing the odds ratio function of rates of uncontrolled blood pressure (SBP≥130mm Hg and/or DBP≥80mm Hg) based on MoCA scores. B, Restricted cubic spline curves showing the odds ratio function of rates of uncontrolled blood pressure (SBP≥140mm Hg and/or DBP≥90mm Hg) based on MoCA scores. C, Restricted cubic spline curves showing the odds ratio function of rates of uncontrolled blood lipids based on MoCA scores. D, Restricted cubic spline curves showing the odds ratio function of rates of uncontrolled blood glucose based on MoCA scores Regarding blood glucose control, compared to normal cognition, MCI was associated with a higher rate of controlled blood glucose [65.5% vs. 56.6%, aOR (95% CI): 1.40 (1.21–1.61), P < 0.001], dementia patients demonstrate a more rapid increase in the rate of uncontrolled blood glucose [67.1% vs. 56.6%, aOR (95% CI): 1.47 (1.09–1.99), P = 0.012]. As the severity of cognitive impairment increased, the rate of uncontrolled blood glucose increased (Table 3; Fig. 2). Subgroup analyses The results presented a similar tendency as the main results in BP, blood lipids, and blood glucose management (Figs. 3, 4, 5 and 6). The analyses were robust, as most outcomes remained similar after adjustments for confounders. The association between cognitive function and the rate of uncontrolled blood pressure (SBP ≥ 130mmHg and/or DBP ≥ 80mmHg) in subgroup. SBP, systolic blood pressure; DBP, diastolic blood pressure; OR, odds ratio; CI, confidence interval; BMI, body mass index; MoCA, Montreal Cognitive Assessment. The association between cognitive function and the rate of uncontrolled blood pressure (SBP ≥ 140mmHg and/or DBP ≥ 90mmHg) in subgroups. SBP, systolic blood pressure; DBP, diastolic blood pressure; OR, odds ratio; CI, confidence interval; BMI, body mass index; MoCA, Montreal Cognitive Assessment The association between cognitive function and the rate of uncontrolled blood lipids in subgroups. OR, odds ratio; CI, confidence interval; BMI, body mass index; CAD, coronary artery disease; MoCA, Montreal Cognitive Assessment The association between cognitive function and the rate of uncontrolled blood glucose (HbA1c ≥ 7%) in subgroups. HbA1c, hemoglobin A1c; OR, odds ratio; CI, confidence interval; BMI, body mass index; MoCA, Montreal Cognitive Assessment Discussion This large cross-sectional study demonstrates that patients with cognitive impairment have a higher prevalence of uncontrolled CVRF, particularly poor glycemic control. Although rates of uncontrolled blood pressure and dyslipidemia were also elevated in this population, the differences did not reach statistical significance. These findings are consistent with previous reports suggesting that cognitive deficits may be associated with impaired self-management, suboptimal medication adherence, and reduced disease understanding, contributing to poorer management of chronic conditions [9–13]. Cognitive impairment may be linked to difficulties in understanding complex treatment regimens, recognizing early symptoms of disease, and maintaining adherence to lifestyle and pharmacological interventions [14–17]. Consequently, management of common CVRF—including blood pressure, blood glucose, lipid levels, dietary restrictions, physical activity, and timely medical follow-up—can be particularly challenging in this population [17–19]. Previous studies have similarly reported that patients with cognitive impairment are more likely to present with uncontrolled hypertension, hyperlipidemia, and diabetes due to limitations in self-management abilities [9–13, 35, 36]. The current findings provide updated estimates of these associations, emphasizing the need for targeted interventions and proactive monitoring to optimize risk factor control among cognitively impaired individuals. The cross-sectional design does not allow for disentangling the bidirectional relationship between CVRF and cognitive decline; poor CVRF control may precede cognitive impairment, while cognitive deficits may be associated with suboptimal risk management [37]. Regardless of causality, these findings indicate that cognitive impairment—even mild cognitive decline—can serve as a marker for higher risk of uncontrolled blood glucose, underscoring the potential value of early cognitive screening and tailored interventions. Self-care is a cognitively demanding process that requires responding to cues, making decisions, processing disease knowledge, and performing self-management tasks effectively [10]. For example, key self-care behaviors in HTN comprise adhering to medication regimens, ensuring dietary sodium restrictions, engaging in regular exercise, maintaining a healthy weight, ensuring adequate sleep, monitoring blood pressure regularly, as well as recognizing, managing, and seeking medical advice when symptoms change [9, 26]. HTN, hyperglycemia, and hyperlipidemia commonly coexist as comorbidities, complicating their management, particularly in patients with cognitive impairment. Managing these conditions often involves multiple medications with varying dosages, schedules, and specific instructions, making adherence especially challenging. Proper medication use requires complex cognitive processes, including executive function, comprehension, working memory, long-term memory, prospective memory, cognitive flexibility, and reasoning [38]. Cognitive deficits can impair these processes, leading to poor medication adherence and suboptimal management. For example, effective diabetes management necessitates precise medication selection, dosing, and adherence to schedules coordinated with dietary patterns for optimal effect [29]. Beyond pharmacological treatment, lifestyle modifications—such as diet, physical activity, sleep, alcohol consumption, and stress management—are also essential for controlling CVRF. However, patients with cognitive impairment often struggle to follow these recommendations, leading to poor control of risk factors [13]. Consequently, managing these comorbidities in cognitively impaired patients requires a comprehensive, tailored approach that integrates both pharmacological and lifestyle interventions. Effective management depends on a certain level of cognitive function, underscoring the critical role of cognitive health in managing chronic conditions. The MCI represents an intermediate stage between normal cognition and dementia. Although effective treatments for MCI are limited, management of CVRF may slow or partially reverse cognitive decline [5, 7]. In this study, 41.5% of the patients were identified as having MCI. Individuals with MCI and dementia exhibited significantly higher rates of uncontrolled blood glucose compared to those with normal cognition, while differences in blood pressure and lipid control were not statistically significant. As cognitive decline progresses, patients often lose the ability to live independently, further complicating the management of chronic conditions. These findings underscore the importance of early identification of cognitive impairment and proactive management of CVRF. Collaboration between clinicians, patients, and caregivers is essential to optimize adherence, control risk factors, and improve overall clinical outcomes. Incorporating dementia into treatment plans presents significant challenges due to the absence of specific guidelines for this vulnerable patient population. Addressing this gap requires targeted, tailored interventions. Personalized prevention and management of cardiovascular diseases in patients with cognitive impairment, particularly in the context of primary and secondary prevention targeting uncontrolled CVRF, are essential. Given the cognitive challenges these patients face, traditional approaches to uncontrolled CVRF management often fall short. Results suggest that cognitive impairment poses a barrier to effective uncontrolled CVRF management, as the patients frequently struggle to adhere to treatment plans and achieve health goals. To address these challenges, external interventions are critical for improving outcomes. Digital health management and telemedicine offer promising solutions by delivering continuous and personalized care to cognitively impaired individuals [39]. Digital platforms enable real-time monitoring, medication reminders, and customized treatment plans, which can enhance adherence to treatment regimens and improve CVRF control. Previous studies have shown that tools such as mobile apps and wearable devices can support more effective uncontrolled CVRF management by providing continuous reminders and guidance for medication adherence and lifestyle modifications [40–42]. Advanced technologies play a critical role in assisting cognitively impaired individuals, especially those who face difficulties with traditional CVRF healthcare management. Integrating digital technologies into healthcare systems has the potential to bridge gaps in care, optimize uncontrolled CVRF management, and significantly improve the quality of care for this at-risk population. There are some limitations in the study. First, the MoCA score grading only indicates the potential presence of cognitive impairment, and a professional diagnosis is required to rigorously confirm cognitive impairment. Second, as this is a cross-sectional study, causal relationships cannot be established, and further longitudinal studies are needed to strengthen the findings. Third, the data of HTN were based on previously diagnosed cases, which may have led to an underestimation of its prevalence. Finally, information on patients’ use of antihypertensive, lipid-lowering, and hypoglycemic medications was not comprehensively collected, potentially affecting the accuracy of risk factor control analysis. Conclusions Based on a large sample size, the findings of this study highlight the challenges that MCI poses to the management of CVRF, and emphasize the importance of recognizing MCI in clinical decision-making as well as integrating cognitive function improvement into strategies for CVRF management. Targeted interventions, such as clearer medication instructions, enhanced caregiver support, and reminder devices, are essential to improve management and disease control in this high-risk group. Further research, particularly randomized controlled trials, is warranted to provide more robust evidence on CVRF management in patients with cognitive impairment and to evaluate the effectiveness of digital health solutions in optimizing care for this vulnerable population. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Thanks to the participants and personnel in the study for their invaluable collaboration during the development of this study. All authors read and approved the final manuscript. Abbreviations Cardiovascular disease Cardiovascular Mild cognitive impairment Hypertension Montreal Cognitive Assessment Systolic blood pressure Diastolic blood pressure Cardiovascular risk factors Coronary artery disease Heart failure Directed acyclic graph Author contributions All authors contributed to the conception and design of the study. Study design: [Ting Shen; Meiqi Zhao; Liu He]; Experimental operation and data collection: [Siyuan Qiao; Zejun Yang; Mingxiao Li]; Data analysis and result collation: [Ting Shen; Manlin Zhao; Jiaxin Liu; Meilin Xu]; Manuscript drafting: [Ting Shen; Meiqi Zhao; Liu He; Yu Kong]; Review and revision: [Liu He; Xin Li; Changsheng Ma]; All authors commented on previous versions of the manuscript and read and approved the final version. Funding This work was supported by a grant from the Beijing Municipal Commission of Science and Technology (Z241100007724008) and he National Science Foundation of China (grant number: 82270316). Data availability This cross-sectional study used data from the hospital’s electronic medical record system. The datasets generated and analyzed during the current study are not publicly available due to patient privacy protection, but are available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no competing interests. Ethics approval and consent to participate All procedures adhered to relevant laws and institutional guidelines. The study was approved by the Institutional Review Board of Beijing Anzhen Hospital, Ethics Approval No: 2025066x. The requirement for informed consent was waived by the ethics committee due to the non-interventional nature of this study. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Ting Shen and Meiqi Zhao have contributed equally to this work and share the first authorship. Contributor Information Xin Li, Email: leexin9907@126.com. Changsheng Ma, Email: chshma@vip.sina.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement This cross-sectional study used data from the hospital’s electronic medical record system. The datasets generated and analyzed during the current study are not publicly available due to patient privacy protection, but are available from the corresponding author on reasonable request. This cross-sectional study used data from the hospital’s electronic medical record system. The datasets generated and analyzed during the current study are not publicly available due to patient privacy protection, but are available from the corresponding author on reasonable request.